Jade Biosciences Soars 59.94% on Promising Preclinical Data

Jade Biosciences' stock surged 59.94% in pre-market trading on June 9, 2025, driven by the release of promising preclinical data for its anti-APRIL monoclonal antibody, JADE101, at the 62nd ERA Congress.

Jade Biosciences presented data showing that JADE101 has a superior profile with femtomolar APRIL binding affinity, 750 times higher than its competitor sibeprenlimab. In non-human primates, JADE101 demonstrated a 27-day half-life, nearly four times longer than sibeprenlimab, with sustained IgA suppression lasting over 100 days after a single dose. The drug also showed high subcutaneous bioavailability and was designed to avoid immune complex formation risks. At just 4 mg/kg, JADE101 achieved better results than 30 mg/kg of sibeprenlimab.

The company plans to initiate human trials in the second half of 2025, with interim data expected in the first half of 2026. This transition to first-in-human trials represents a critical development milestone that will validate whether these impressive preclinical characteristics translate to human subjects.